Introduction Inflammatory bowel disease (IBD) can have a significant impact on physical, psychological and social wellbeing. We aimed to survey the impact of IBD on our patients’ lives and their perceptions of psychological support use and availability.

Methods Inflammatory bowel disease (IBD) can have a significant impact on physical, psychological and social wellbeing. We aimed to survey the impact of IBD on our patients’ lives and their perceptions of psychological support use and availability.

Results 6 patients were excluded as they had not completed the questionnaire. 94 patients were included (43 male, 51 female, average age 42 years, range 17–76). 46 had a diagnosis of Crohn’s disease, 41 ulcerative colitis and 7 indeterminate colitis. Average disease duration for these patients was 15 years (range 1–51 years). Over the past 6 months 20 had symptoms constantly, 16 often, 17 occasionally, 10 sometimes, 13 rarely and 18 never. The average SIBDQ score was 48 (range 21–70). The average HAD score was 12.6 (range 0–53). When separated into HAD A (anxiety) and HAD D (depression) scores were 8.1 (range 0–18) and 4.8 (range 0–15) on average respectively, a score of 8 to 10 for either subscale being suggestive of the presence of the respective state. They were also asked which services they had previously used as forms of support. Of the 86 patients who answered this portion of the questionnaire, 15 (15%) said they had previously had counselling or psychological input, and 32 (37%) said they would like counselling or psychological input in the future if it was available.

Conclusion Our survey suggests there may be a higher rate of anxiety in patients with IBD, and that over a third of our patients would like access to psychological and counselling services if they were available. Psychological support is important to patients with IBD and should be incorporated into their management.

Disclosure of Interest None Declared.

Conclusion Our study showed 20.2% of IBD patients attending over a one month period had iron deficiency anaemia or iron deficiency. Treatment of iron deficiency with and without anaemia is variable and could improve with adherence to a clear protocol. The question of whether the treatment of iron deficiency without significant anaemia in IBD improves fatigue and QOL requires further research.

Disclosure of Interest None Declared.

**References**

**Disclosure of Interest**

None Declared.

**Disclosure of Interest**

None Declared.

**Disclosure of Interest**

None Declared.

**Disclosure of Interest**

None Declared.

**Disclosure of Interest**

None Declared.
**Introduction**

The pathogenesis of Inflammatory Bowel Disease (IBD) is unclear which hinders effective targeted drug development. IBD and murine models of colitis are associated with the abnormal accumulation of activated dendritic cells (DCs) in the colonic epithelium. DCs play a critical role in promoting inflammatory responses and blockade of their activation prevents colitis development in mouse models. We now propose to address the mechanisms underlying the aberrant accumulation of DCs in the gut by focusing on microbial danger stimuli that drive activation and migration of DCs.

**Methods**

We analysed the expression of migration-associated markers on DCs from normal and colitic mice. Bone marrow-derived DCs (BMDCs) from WT or Beta-2 Integrin-/- (ITGB2-/-) mice were cultured in vitro and their migration and activation analysed in response to control (Phosphone buffered saline - PBS), bacterial lipopolysaccharide (LPS), live Escherichia coli (EC), and live Bacteroides fragilis (BF) in the presence and absence of the lamina propria extra-cellular matrix component fibronectin.

**Results**

During colitis there was a marked increase in a population of CD103+ (αE integrin) DCs. We were able to mirror these populations in vitro. DCs moved via random motion and their velocity after stimulation with LPS and EC, in the absence of fibronectin, was significantly decreased. In comparison, stimulation with BF significantly increased DC velocity (p < 0.001 for all). In the presence of fibronectin, there was no change in DC velocity. The track displacement length (the distance between the start and finishing point of a given cell migration track) was significantly decreased after BF stimulation with LPS and EC, in the absence of fibronectin, was significantly decreased. In comparison, stimulation with BF significantly increased DC velocity (p < 0.001 for all). Unstimulated ITGB2-/- BMDC velocity and track displacement length were significantly increased in comparison to that of unstimulated WT BMDC (p < 0.001 for both). This was more marked in the absence of fibronectin.

**Conclusion**

We have shown that in vitro WT DC cultures contain DCs with similar integrin-defined phenotypes to those found in colonic DCs in colitis. Differential bacterial stimulation causes opposing fibronectin-dependent effects on BMDC migratory behaviour whilst absence of ITGB2 significantly alters the migratory behaviour of BMDC. Our data implicates a complex relationship between specific components of gut microbiota, extracellular matrix, and migration and activation of DCs that could potentiate the aberrant accumulation of DCs in the colitic gut. If this complex relationship is further elucidated, it may be possible in the future to develop therapies that reduce colitis by controlling DC migration.

**Disclosure of Interest**

None Declared.

---

**PTH-104**

**THE ROUTINE MEASUREMENT OF THIOPURINE METABOLITE LEVELS RESULTS IN DOSE OPTIMISATION IN ONE THIRD OF IBD PATIENTS: RESULTS FROM A DISTRICT GENERAL HOSPITAL**

doi:10.1136/gutjnl-2013-304907.591

1H M Dewhurst, 2H E Johnson, 3J Begley, 4S A Weaver, 2,*S D McLaughlin.

1Research; 2Gastroenterology; 3Clinical Biochemistry, Royal Bournemouth Hospital, Bournemouth, UK

**Introduction**

Measuring azathioprine or mercaptopurine (AZA) metabolite levels 6-TGN and 6-MMPN allows identification of patients who are: 1. Non compliant with their medication. 2. On a sub-optimal dose. 3. On a supra-therapeutic dose. 4. Are preferentially metabolising azathioprine to methylated metabolites (6-MMPN/6-TGN ratio > 1).

Our own and others published data demonstrate that measuring metabolite levels in patients failing azathioprine therapy followed by appropriate changes in dosing and/or the addition of allopurinol (with 75% dose reduction in AZA) can result in clinical remission in the majority of patients. 1 We report the outcome of the routine measurement of metabolite levels in patients treated with AZA who were in a clinical remission without side effects or abnormal liver function tests (LFTs).

**Methods**

All patients underwent TPMT testing, azathioprine and mercaptopurine were initiated at doses of 2mg/kg and 1mg/kg respectively in those with wild-type TPMT with a 50% reduction in dose in TPMT heterozygotes. We searched the prospective database maintained by our biochemistry department for all patients who underwent metabolite level testing from September 2011 to November 2012, hospital case notes for these patients were reviewed. The indications, results of testing, changes in clinical management and patient outcomes were recorded.

**Results**

108 patients underwent metabolite testing, median length of follow-up since testing was 287.6 days (range 21–441), all were stable on AZA for ≥ 4 weeks with normal LFTs and in a clinical remission. 38 (35.2%) had UC, 66 (61.1%) CD, 52 (48.1%) were male.

17 (15.7%) patients had a sub-therapeutic 6-TGN, 10 (9.3%) supra-therapeutic 6-TGN level (> 800) all of whom had dose optimisation. 6 (5.6%) patients were hypermethylators these were switched to allopurinol co-therapy with an appropriate reduction in AZA dose.

**Conclusion**

In the present study the routine measurement of AZA metabolites resulted in a change in clinical management in 30.6% of patients.

Whilst unproven in prospective longitudinal studies logic suggests that the routine measurement of AZA metabolites in all patients commenced on thiopurines followed by appropriate dose optimisation (with or without allopurinol co-prescription) should reduce or prevent the development of drug side effects, abnormal LFTs and bone marrow suppression and reduce the risk of disease relapse. We recommend that AZA metabolite testing is performed in all patients 4–6 weeks after commencing AZA.

**Disclosure of Interest**

None Declared.

---

**PTH-105**

**THE EFFECT OF INFliximab PRE-TREATED HUMAN BLOOD-ENRICHED DENDRITIC CELLS FROM PATIENTS WITH ACTIVE CROHN’S DISEASE AND HEALTHY CONTROLS ON SUBSEQUENT HUMAN T-LYMPHOCYTE PHENOTYPE AND CYTOKINE PRODUCTION IN VITRO**

doi:10.1136/gutjnl-2013-304907.592

11'T C Te Peake, 2'D Bernardo, 3'E Mann, 4'L Landy, 5'H Omar, 6'S C Knight, 7'A L Hart. 1IBD Unit, St Mark’s Hospital; 2APRG, Imperial College, London, UK

**Introduction**

Dendritic cells (DC) play a key role in discriminating between commensal microorganisms and potentially harmful pathogens. Expression of surface markers and cytokine production by DC at the time of antigen presentation correlate with disease differentiation, cytokine profile & homing properties imprinted on stimulated T-cells. This process defines the type of immune response that occurs and its anatomic location. In CD, dysregulation of the immune response to gut microbiota and aberrant immune cell trafficking play a central role in disease pathogenesis. Infliximab (IFX) is an effective treatment for CD, but its mechanism of action is unclear. In this study, we investigated the effect of IFX pre-treated blood-enriched DC, isolated from patients with active CD and healthy controls (HC), on human T-cell proliferation, phenotype & cytokine production.

**Methods**

Low density cells (LDC), enriched for DC, were obtained following Ficol and Nycoprep gradient separation of fresh blood from patients with active ileocolonic CD (CDAI > 220) and HC. LDC were cultured (0.5x10^6 cells/ml) with IFX (1:10ug/800ug/ml/2000) for 24hr. T-cells were enriched from allogeneic HC blood and labelled with CFSE. LDC were added to T-cells in complete medium (400,000cells/ml) at basal,1.25% concentrations and incubated for 5days. Following incubation, T-cell proliferation,